CA Patent

CA2964168C — Therapeutic inhibition of lactate dehydrogenase and agents therefor

Assigned to Novo Nordisk Health Care AG · Expires 2025-08-12 · 1y expired

What this patent protects

This invention relates to compounds, compositions, and methods useful for reducing lactate dehydrogenase target RNA and protein levels via use of dsRNAs, e.g.. Dicer substrate siRNA (DsiRNA) agents.

USPTO Abstract

This invention relates to compounds, compositions, and methods useful for reducing lactate dehydrogenase target RNA and protein levels via use of dsRNAs, e.g.. Dicer substrate siRNA (DsiRNA) agents.

Drugs covered by this patent

Patent Metadata

Patent number
CA2964168C
Jurisdiction
CA
Classification
—
Expires
2025-08-12
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk Health Care AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.